Laboratory News and Research

RSS

A shot to lower 'bad' cholesterol

Patients unable to control their cholesterol levels with medications may someday be able to lower their "bad" cholesterol with a shot, according to research presented at the American Heart Association's Scientific Sessions 2011.

14 Nov 2011

Sinovac third quarter sales increase 60.8% to $15.4 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for the period ended September 30, 2011.

14 Nov 2011

Study uses fMRI to assess changes in brain after exercise intervention

Areas of the brain responsible for pain processing and cognitive performance changed in fibromyalgia patients who exercised following a medication holiday, say researchers from Georgetown University Medical Center. They say the changes indicate brain functioning is more streamlined after an exercise intervention because less of the brain-s resources is devoted to processing bothersome fibromyalgia perceptions such as pain.

14 Nov 2011

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

In the last three decades, thousands of women with breast cancer have taken the drug tamoxifen, only to discover that the therapy doesn't work, either because their tumors do not respond to the treatment at all, or because they develop resistance to it over time. Now researchers at the University of California, San Francisco (UCSF) have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it.

14 Nov 2011

Scientists identify factors that lead to concomitant tumor resistance

Scientists are another step closer to understanding what drives tumor metastasis, as laboratory models suggest there are factors inside tumors that can slow their own growth.

14 Nov 2011

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.

14 Nov 2011

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

14 Nov 2011

Health supplement hope for child muscle disease

A health supplement used by bodybuilders could be the key to treating a life-threatening muscular dystrophy affecting hundreds of Australian children, new research shows.

14 Nov 2011

Researchers retrace evolution of unusual bacterial infection

Researchers at Harvard Medical School and Children's Hospital Boston have retraced the evolution of an unusual bacterial infection as it spread among cystic fibrosis patients by sequencing scores of samples collected during the outbreak, since contained.

14 Nov 2011

UM to host Summit on Childhood Obesity at Hilton Baltimore

Science and medical reporters are invited to sample a wide diversity of new research and policy initiatives at a Summit on Childhood Obesity on Tues., Nov. 15 and Wed., Nov. 16 at the Hilton Baltimore.

13 Nov 2011

Brazilian Ministry of Health, Bristol-Myers Squibb sign technology transfer agreement for Reyataz

Bristol-Myers Squibb Company today announced a technology transfer agreement with the Brazilian Ministry of Health to expand access to Reyataz (atazanavir sulfate) in Brazil.

13 Nov 2011

Oncostatin M could help heal damaged heart muscle tissue

Oncostatin M regulates the reversion of heart muscle cells into precursor cells and is vitally important for the self-healing powers of the heart

11 Nov 2011

Scientists suppress NCoR1 protein and create mighty mice

A team of researchers at EPFL, the University of Lausanne and the Salk Institute created super strong, marathon mice and nematodes by reducing the function of a natural inhibitor, suggesting treatments for age-related or genetically caused muscle degeneration are within reach.

11 Nov 2011

Berkeley Lab, Bruker partner to develop and distribute new structural biology methods

Bruker Corporation and Lawrence Berkeley National Laboratory (Berkeley Lab) today announced a collaboration to develop and distribute new structural biology methods and tools to integrate Small-Angle X-ray Scattering (SAXS) with Nuclear Magnetic Resonance.

11 Nov 2011

Study: Primary visual cortex is modulated only by attention

In everyday life, attention and awareness appear tightly interwoven. Attending to the scissors on the rinumber of behavioural observations have recently led scientists to postulate that attention and awareness are fundamentally different processes and not necessarily connected.ght side of your desk, you become aware of their attributes, for example the red handles. Vice versa, the red handles could attract your attention to the scissors.

11 Nov 2011

Intelligent Fingerprinting launches prototype of hand-held drug testing device

The world's first prototype of a hand-held fingerprint drug testing device has been created by UK technology company Intelligent Fingerprinting.

11 Nov 2011

Long-range wind transport of an infectious agent may cause KD

Kawasaki Disease (KD) is a severe childhood disease that many parents, even some doctors, mistake for an inconsequential viral infection. In fact, if not diagnosed or treated in time, it can lead to irreversible heart damage. After 50 years of research, including genetic studies, scientists have been unable to pinpoint the cause of the disease.

10 Nov 2011

Enzyme research may lead to drugs with fewer side effects

A tree outside Oak Ridge National Laboratory researcher Pratul Agarwal's office window provided the inspiration for a discovery that may ultimately lead to drugs with fewer side effects, less expensive biofuels and more.

10 Nov 2011

IRCM peptide chemist listed as inventor on two U.S. patents

In 2010, after more than 10 years of basic research, Dr. Peter W. Schiller, a world-renowned peptide chemist and Director of the Chemical Biology and Peptide research unit at the Institut de recherches cliniques de Montr-al (IRCM), and his international collaborators were the listed inventors on two U.S. patents awarded to the institute and covering different uses of a unique class of peptide compounds initially synthesized in Dr. Schiller's laboratory at the IRCM.

10 Nov 2011

CCCBD scientist to receive 2011 V Foundation Translational Research Grant

Scientists at the Children's Center for Cancer and Blood Diseases (CCCBD) and the Keck School of Medicine of the University of Southern California, have been awarded a highly competitive translational research grant of $600,000 from The V Foundation for Cancer Research.

10 Nov 2011